Bluebird Bio Inc. (BLUE) Earns Buy Rating from Analysts at Roth Capital
Roth Capital started coverage on shares of Bluebird Bio Inc. (NASDAQ:BLUE) in a research note issued to investors on Thursday. The brokerage set a “buy” rating and a $87.00 price target on the stock. Roth Capital’s target price points to a potential upside of 17.87% from the company’s previous close.
Several other research analysts have also weighed in on the company. Goldman Sachs Group Inc. reissued a “buy” rating and issued a $135.00 price objective on shares of Bluebird Bio in a research report on Thursday, August 18th. Zacks Investment Research raised Bluebird Bio from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. BTIG Research reaffirmed a “buy” rating and issued a $72.00 target price on shares of Bluebird Bio in a research report on Wednesday, June 29th. Jefferies Group reaffirmed a “positive” rating and issued a $80.00 target price on shares of Bluebird Bio in a research report on Thursday, July 14th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $117.00 target price on shares of Bluebird Bio in a research report on Wednesday, August 3rd. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $89.17.
Shares of Bluebird Bio (NASDAQ:BLUE) traded down 2.06% during mid-day trading on Thursday, reaching $72.29. The company had a trading volume of 271,612 shares. The stock’s market capitalization is $2.69 billion. The firm’s 50 day moving average is $57.02 and its 200-day moving average is $48.11. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $113.26.
Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. The company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $2.01 million. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The firm’s revenue for the quarter was down 68.6% on a year-over-year basis. During the same period in the prior year, the business earned ($1.57) earnings per share. On average, analysts expect that Bluebird Bio will post ($6.16) earnings per share for the current fiscal year.
In other news, insider Eric Sullivan sold 2,912 shares of the company’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $55.01, for a total value of $160,189.12. Following the transaction, the insider now owns 4,456 shares of the company’s stock, valued at $245,124.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David Davidson sold 1,000 shares of the company’s stock in a transaction on Friday, July 15th. The stock was sold at an average price of $45.08, for a total transaction of $45,080.00. Following the completion of the transaction, the insider now directly owns 10,600 shares in the company, valued at approximately $477,848. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by insiders.
A number of hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new stake in Bluebird Bio during the first quarter valued at about $51,095,000. BlackRock Inc. raised its stake in Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock valued at $194,000 after buying an additional 3,533 shares during the last quarter. California State Teachers Retirement System raised its stake in Bluebird Bio by 2.2% in the second quarter. California State Teachers Retirement System now owns 77,687 shares of the company’s stock valued at $3,363,000 after buying an additional 1,682 shares during the last quarter. Iguana Healthcare Management LLC acquired a new stake in Bluebird Bio during the first quarter valued at about $1,030,000. Finally, Swiss National Bank raised its stake in Bluebird Bio by 10.6% in the second quarter. Swiss National Bank now owns 59,707 shares of the company’s stock valued at $2,585,000 after buying an additional 5,700 shares during the last quarter.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.